Protocol for a pragmatic cluster randomised controlled trial assessing the clinical effectiveness and cost-effectiveness of Electronic RIsk-assessment for CAncer for patients in general practice (ERICA)

Author:

Hamilton WillieORCID,Mounce LukeORCID,Abel Gary AORCID,Dean Sarah GerardORCID,Campbell John L,Warren Fiona CORCID,Spencer Anne,Medina-Lara Antonieta,Pitt Martin,Shephard Elizabeth,Shakespeare Marijke,Fletcher EmilyORCID,Mercer Adrian,Calitri RaffORCID

Abstract

IntroductionThe UK has worse cancer outcomes than most comparable countries, with a large contribution attributed to diagnostic delay. Electronic risk assessment tools (eRATs) have been developed to identify primary care patients with a ≥2% risk of cancer using features recorded in the electronic record.Methods and analysisThis is a pragmatic cluster randomised controlled trial in English primary care. Individual general practices will be randomised in a 1:1 ratio to intervention (provision of eRATs for six common cancer sites) or to usual care. The primary outcome is cancer stage at diagnosis, dichotomised to stage 1 or 2 (early) or stage 3 or 4 (advanced) for these six cancers, assessed from National Cancer Registry data. Secondary outcomes include stage at diagnosis for a further six cancers without eRATs, use of urgent referral cancer pathways, total practice cancer diagnoses, routes to cancer diagnosis and 30-day and 1-year cancer survival. Economic and process evaluations will be performed along with service delivery modelling. The primary analysis explores the proportion of patients with early-stage cancer at diagnosis. The sample size calculation used an OR of 0.8 for a cancer being diagnosed at an advanced stage in the intervention arm compared with the control arm, equating to an absolute reduction of 4.8% as an incidence-weighted figure across the six cancers. This requires 530 practices overall, with the intervention active from April 2022 for 2 years.Ethics and disseminationThe trial has approval from London City and East Research Ethics Committee, reference number 19/LO/0615; protocol version 5.0, 9 May 2022. It is sponsored by the University of Exeter. Dissemination will be by journal publication, conferences, use of appropriate social media and direct sharing with cancer policymakers.Trial registration numberISRCTN22560297.

Funder

Macmillan Cancer Support

The Dennis and Mireille Gillings Foundation

Cancer Research UK

University of Exeter

Publisher

BMJ

Subject

General Medicine

Reference40 articles.

1. The size of the prize for earlier diagnosis of cancer in England

2. Richards M , Thorlby R , Fisher R , et al . Unfinished business: an assessment of the national approach to improving cancer services in England 1995–2015. London, 2018.

3. NHS England . The NHS long term plan. 2019. Available: www.longtermplan.nhs.uk/

4. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial

5. Richards M . THE INDEPENDENT REVIEW OF ADULT SCREENING PROGRAMMES. NHS England, 2019.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3